Alejandro Andrés Gracia

ORCID: 0000-0003-3501-0121
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Parathyroid Disorders and Treatments
  • IgG4-Related and Inflammatory Diseases
  • Cellular transport and secretion
  • Peptidase Inhibition and Analysis
  • Protein Kinase Regulation and GTPase Signaling
  • Neuroendocrine Tumor Research Advances
  • Eosinophilic Disorders and Syndromes
  • Medical Imaging and Pathology Studies
  • Genetic and Kidney Cyst Diseases
  • Soft tissue tumor case studies
  • Surgical site infection prevention
  • History, Medicine, and Leadership
  • HER2/EGFR in Cancer Research
  • Vascular Malformations and Hemangiomas
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Renal and related cancers
  • Tumors and Oncological Cases
  • Liver Diseases and Immunity
  • Lung Cancer Research Studies
  • Cardiomyopathy and Myosin Studies
  • Autoimmune Bullous Skin Diseases
  • Cutaneous lymphoproliferative disorders research
  • Inflammatory Bowel Disease
  • Infectious Aortic and Vascular Conditions

Hospital Clínico Universitario Lozano Blesa
2014-2025

Instituto de Investigación Sanitaria Aragón
2019-2024

Background: Therapy using lutetium-177 dotatate (177LU) was approved in Europe for the treatment of advanced neuroendocrine tumors (NETs) 2017. Since then, it has become part strategies NETs, making now possible to evaluate real-life results. Research Design and Methods: Single-arm, retrospective, multicenter, cohort study all patients with metastatic NETs treated 177LU (four cycles 200 mCi every 8 weeks) two medical centers dedicated from region Aragón, Spain, 2017 2024. Descriptive...

10.3390/jcm14072384 article EN Journal of Clinical Medicine 2025-03-30
Carlos Ferrando César Aldecoa Carmen Unzueta F. J. Belda Julián Librero and 95 more Gerardo Tusman Fernando Suárez-Sipmann Salvador Peiró Natividad Pozo Andrea Brunelli Ignacio Garutti Clara Gallego Aurelio Rodríguez Jose I. García Óscar Díaz‐Cambronero Jaume Balust Francisco Javier Redondo Calvo Manuel de la Matta Lucía Gallego Javier Hernández Pascual Martínez Ana María Pérez Sonsoles Leal Enrique Alday Pablo Monedero Rafael González Guido Mazzirani Gerardo Aguilar Manuel López-Baamonde M A Nalda Felipe Ana Mugarra Jara Torrente Lucía Valencia Viviana Varón Sergio Sánchez‐García Benigno Rodríguez A. Esteban Martín Inmaculada India Gonzalo Azparren Rodrigo Molina Jesús Villar Marina Soro Jesús Acosta María José Alberola Amalia Alcón Rosa Almajano Carlos Álvaréz Rafael Anaya Cristian C. Aragón Marta Argilaga Blanca Arocas Begoña Ayas Victor Balandrón Elizabeth Bárcena Natalia Bejarano Luis Jesús Belmonte Ureña Vanesa Berges Maria Guillén Bermejo Rafael Cabadas Sergio Cabrera Raquel Callejas J Carbonell Juan Carrizo J Castillo Pedro Charco-Mora Ana Fanlo Colás Lorena Colomina Laura Cotter Patrícia Cruz Javier Cuervo Gema Del Castillo Elena del Río Juan F. Delgado Carlos Dexeus Rubén Sierra Díaz Mandalina Dinu Alejandro Duca Patricia Duque Gemma Echarri Patricia Fabra Carmen Cagigas Fernández Raluca Florea Pilar Forcada Isabel Fuentes Cristina Garcés S. García del Valle Beatriz García Esther García María Bóveda García Mercedes García B. Garrigues Ignacio Garutti Fernando Gil Domingo González Alejandro Andrés Gracia Estefanía Gracia Manuel Granell Yessica Guerra Andrea Gutiérrez Julia Hernando

10.1016/j.bja.2019.10.009 article EN publisher-specific-oa British Journal of Anaesthesia 2019-11-22

Cardiac amyloidosis (CA), following a non-invasive diagnosis, constitutes an increasingly prevalent heart failure (HF) etiology. This study aims to determine which echocardiography findings help diagnose CA in patients with left ventricular hypertrophy (LVH) admitted for decompensated HF.The present is retrospective observational on cohort of 85 LVH HF decompensation, 99mTc-DPD scanning was performed rule out transthyretin CA. The echocardiographic obtained were compared between and non-CA...

10.5603/cj.a2021.0085 article EN cc-by-nc-nd Cardiology Journal 2021-08-06

<b><br>Introduction:</b> Although PET/CT is effective for staging HNSCC, its impact on patient management somewhat controversial. For this reason, we considered it necessary to carry out a study in order verify whether helps improve the prognosis and treatment patients. This was designed address of PET-FDG imaging when used alongside CT therapeutic patients with HNSCC.</br> <b><br>Material methods:</b> Data collected from 169 diagnosed HNSCC both...

10.5604/01.3001.0054.2561 article EN Otolaryngologia Polska 2024-02-23

Background: Countless confounding factors have been described in the interpretation of incidental myocardial uptakes. Among them, prostate cancer is probably most important. While some authors may defend benign etiology these uptakes, others propose a further study to rule out amyloid cardiomyopathy. Objective: Our aim investigate clinical relevance uptakes bone scans requested evaluate prostatic neoplasia, assessing possibility that correspond cardiac amyloidosis (CA). Methods:...

10.24018/ejmed.2024.6.2.2018 article EN European Journal of Medical and Health Sciences 2024-04-30

Amyloidosis is a heterogeneous group of diseases caused by abnormal extracellular deposition insoluble proteins and can involve myocardium. One the causes myocardial involvement TTR amyloidosis. Our objective has been to evaluate situation cardiac amyloidosis (CA) in our center role nuclear medicine, review state art medicine this entity.We have evaluated retrospectively 186 patients with clinical suspicion CA analyzed characteristics, free light chains immunofixation serum and/or urine,...

10.1097/rlu.0000000000003553 article EN Clinical Nuclear Medicine 2021-02-27

Cardiac involvement is common in amyloidosis, and the vast majority of cases amyloid cardiomyopathy are attributed to primary amyloidosis or transthyretin (ATTR). Although coexistence scintigraphy suggestive ATTR with monoclonal gammopathy undetermined significance well documented, correct diagnosis still challenging non-referral centers.We performed a retrospective study reviewing all diagnosed at our center over last 5 years, described experience diagnostic approach.During 74 patients...

10.6515/acs.202203_38(2).20210927a article EN PubMed 2022-03-01

Wild-type transthyretin (ATTRwt) amyloidosis is caused by the misfolding and deposition of protein (TTR) in absence mutations TTR gene. Studies regarding variant form ATTR (ATTRv) suggest that presence single-nucleotide polymorphisms (SNP) genes other than TTR, may influence development disease. However, genetic factors involved aetiopathogenesis ATTRwt are currently unknown. This work investigates sequence variants selected for their possible impact on amyloidosis. To do so, targeted...

10.1186/s13104-023-06491-z article EN cc-by BMC Research Notes 2023-10-02
Coming Soon ...